This page uses content from Wikipedia and is licensed under CC BY-SA.

Dusigitumab

Dusigitumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetILGF2
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
KEGG
Chemical and physical data
FormulaC6372H9824N1700O2016S54
Molar mass151 kg/mol g·mol−1

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2.[1] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[2]

References